Mogelijk gemaakt door 
Translate
Translate
Late-breaker abstract accepted for oral presentation on the interim analysis of cough in patients with idiopathic pulmonary fibrosis (IPF) at the upcoming European Respiratory Society International Congress 2022, Barcelona, Spain, September 4-6
Late-breaker abstract accepted for oral presentation on topline data for the treatment of prurigo nodularis (PN) at upcoming 31st European Academy of Dermatology and Venereology Congress, Milan, Italy, September 7-10
NEW HAVEN, Conn., Aug. 24, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced two late-breaking abstracts were accepted for presentation at upcoming fall medical conferences. The previously disclosed positive interim data from CANAL, a phase 2 trial for chronic cough in IPF, will be presented as an oral late-breaker abstract presentation at the European Respiratory Society (ERS) International Congress 2022 in Barcelona, Spain. The previously disclosed positive topline data from PRISM, a phase 2b/3 trial in PN, will be presented as an oral late-breaker abstract presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy.
Conference Details
ERS (European Respiratory Society) International Congress 2022 (September 4-6) | |
Session: | What is hot in interstitial lung diseases |
Title: | An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis |
Location: | Barcelona, Spain |
Presentation: | September 4, 2:50 PM CET |
Presenter: | Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California |
Registration Details: | |
31st EADV (European Academy of Dermatology and Venereology) Congress (September 7-10) | |
Session: | D2T01.3: Late Breaking News |
Title: | Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study |
Location: | Milan, Italy |
Presentation: | September 9, 5:00 PM CEST |
Presenter: | Sonja Ständer, MD, Professor of Dermatology and Neurodermatology at the University Hospital Münster |
Registration Details: | |
Trevi Therapeutics announces multiple late-breaking abstracts accepted for presentation at upcoming medical conferences
The CANAL (Cough And NALbuphine) trial is a Phase 2 double-blind, randomized, placebo-controlled, 2-treatment, 2-period crossover efficacy and safety study of nalbuphine ER for chronic cough in IPF. Statistically significant efficacy results from the interim analysis (N=26) were announced:
